Roche Stops Work on Experimental SMA Drug

Roche stops work on experimental SMA drug

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study.

Roche Ends Trial for SMA Drug Emugrobart, Handing Market Edge to Scholar Rock

Roche and its subsidiary Genentech have officially halted the development of emugrobart, an investigational anti-myostatin therapy for Spinal Muscular Atrophy (SMA), following disappointing Phase 2/3 MANATEE study results. While the drug was well-tolerated with no safety concerns, it failed to provide the consistent improvements in muscle growth and motor function expected when combined with the company’s existing drug, Evrysdi. Consequently, Ro…

Genentech stops emugrobart program for SMA after trial results

Genentech has stopped developing emugrobart after trial results showed no consistent benefit when added to Evrysdi in people with SMA.

Roche drops Phase III plans for emugrobart in two muscle wasting diseases

Roche will no longer progress emugrobart to late-stage trials in FSHD and SMA, as the drug has failed to demonstrate muscle-building efficacyThe post Roche drops Phase III plans for emugrobart in two muscle wasting diseases appeared first on Clinical Trials Arena.

Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial

Roche's subsidiary Genentech has called off the late-stage development of a muscle-building drug in two rare genetic conditions, spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). The move raises questions about whether the drug ...